Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 1,034 Shares

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 1,034 shares of the business’s stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $10.00, for a total transaction of $10,340.00. Following the sale, the chief financial officer now owns 100,783 shares in the company, valued at approximately $1,007,830. This trade represents a 1.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Dominic Piscitelli also recently made the following trade(s):

• On Tuesday, June 24th, Dominic Piscitelli sold 32,466 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.50, for a total transaction of $340,893.00.
• On Thursday, June 12th, Dominic Piscitelli sold 300 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,000.00.
• On Wednesday, June 11th, Dominic Piscitelli sold 2,976 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.01, for a total transaction of $29,789.76.
• On Tuesday, June 10th, Dominic Piscitelli sold 324 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.00, for a total value of $3,240.00.
• On Monday, June 9th, Dominic Piscitelli sold 300 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.00, for a total value of $3,000.00.
• On Friday, June 6th, Dominic Piscitelli sold 2,600 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.01, for a total value of $26,026.00.

Oric Pharmaceuticals Stock Performance

ORIC opened at $10.23 on Thursday. The stock has a market capitalization of $871.80 million, a P/E ratio of -5.47 and a beta of 1.49. The company’s 50-day simple moving average is $6.93 and its two-hundred day simple moving average is $7.70. Oric Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.09. Research analysts forecast that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Oric Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ORIC. KLP Kapitalforvaltning AS purchased a new position in shares of Oric Pharmaceuticals in the fourth quarter worth approximately $50,000. BNP Paribas Financial Markets bought a new position in Oric Pharmaceuticals in the fourth quarter worth approximately $71,000. Arizona State Retirement System bought a new position in Oric Pharmaceuticals in the first quarter worth approximately $56,000. PNC Financial Services Group Inc. boosted its stake in shares of Oric Pharmaceuticals by 22.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock worth $109,000 after acquiring an additional 2,520 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new stake in shares of Oric Pharmaceuticals during the 4th quarter valued at $118,000. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on ORIC. JPMorgan Chase & Co. lifted their price target on Oric Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Tuesday, May 6th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Oric Pharmaceuticals in a research report on Monday, May 5th. Oppenheimer lowered their price target on Oric Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating for the company in a research report on Tuesday, May 6th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Oric Pharmaceuticals in a research report on Monday. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $19.17.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.